Table 2.
Baseline patient demographics and clinical characteristics in the pancreatitis and random comparator groups classified as serious adverse events
| Characteristic | Pancreatitis group n = 195 |
Random comparator group n = 195 |
p value |
|---|---|---|---|
| Sex, n (%) | |||
| Male | 92 (47.2) | 75 (38.5) | 0.101 |
| Female | 90 (46.2) | 115 (59.0) | 0.015 |
| Unknown | 13 (6.7) | 5 (2.6) | – |
| Patients with known age, n | 139 | 165 | – |
| Mean age, years | 39.5 (15.8) | 48.8 (17.2) | – |
| Vedolizumab indication for use, n (%) | |||
| Crohn’s disease | 56 (28.7) | 88 (45.1) | 0.001 |
| Ulcerative colitis | 79 (40.5) | 75 (38.5) | 0.756 |
| IBD unspecifieda | 22 (11.3) | 15 (7.7) | |
| Unknown or otherb | 38 (19.5) | 17 (8.7) | |
IBD inflammatory bowel disease
aIncludes “other IBD,” “IBD other,” and “IBD unspecified”
bIncludes “unknown,” “not reported,” and “other”